Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-03-07-Speech-1-204-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-03-07"^^xsd:date2
dcterms:Is Part Of	lp_eu:Management of H1N1 influenza (short presentation)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20110307.23.1-204-000"2
lpv:hasSubsequent	lp_eu:2011-03-07-Speech-1-204-5002
lpv:speaker	lp:Bogusław Sonik2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 member; Delegation for relations with Iran (2009-09-16--2014-06-30)3 unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3 substitute; LIBE (2009-07-16--2012-01-18)3 vice-chair; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"The work on the report on the A/H1N1 virus pandemic in 2009–2010 lasted nearly one year. The discussion initiated in the European Parliament ended with an own-initiative report by the Committee on the Environment, Public Health and Food Safety on swine flu, which contained points emphasising the ethical and procedural irregularities which occurred while fighting the disease. We were concerned about the ways the pharmaceutical companies publicised the issue of swine flu, presenting the virus as very dangerous and virulent. The virus proved to be much less dangerous than ordinary flu. The number of deaths stood at 2 900, while the estimated number of cases attributable to seasonal influenza amounts to 40 000 per year. The report on the evaluation of the management of H1N1 influenza in the European Union calls for the independence of the EU when it comes to developing its own assessment of the seriousness of threats and the risks arising from them, rather than relying on the research of experts funded by pharmaceutical companies. At the same time, the suspect fast-track procedure used to introduce vaccines against H1N1 to the market, without sufficient tests and examinations, also raises criticism. I would like to emphasise the need for increased transparency concerning the activities of EU institutions in the field of disease management, a review of existing procedures and their amendment towards greater flexibility, and the avoidance of conflicts of interest among evaluators and decision makers. I consider the call for the cooperation of countries to strengthen their negotiating position when buying drugs a priority. However, I would like to maintain the voluntary principle when it comes to the purchase of vaccines."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph